Bokf Na Takes $249,000 Position in argenx SE (NASDAQ:ARGX)

Bokf Na bought a new position in shares of argenx SE (NASDAQ:ARGX) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 668 shares of the company’s stock, valued at approximately $249,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sequoia Financial Advisors LLC bought a new position in shares of argenx during the 4th quarter worth approximately $598,000. Avidity Partners Management LP raised its position in shares of argenx by 27.1% in the fourth quarter. Avidity Partners Management LP now owns 625,000 shares of the company’s stock valued at $236,769,000 after purchasing an additional 133,200 shares during the period. DAVENPORT & Co LLC lifted its stake in shares of argenx by 21.2% during the 1st quarter. DAVENPORT & Co LLC now owns 1,365 shares of the company’s stock worth $509,000 after buying an additional 239 shares during the last quarter. ExodusPoint Capital Management LP boosted its holdings in shares of argenx by 62.6% during the 4th quarter. ExodusPoint Capital Management LP now owns 17,433 shares of the company’s stock worth $6,604,000 after buying an additional 6,712 shares during the period. Finally, Guggenheim Capital LLC grew its stake in argenx by 177.9% in the 1st quarter. Guggenheim Capital LLC now owns 8,569 shares of the company’s stock valued at $3,193,000 after buying an additional 5,485 shares during the last quarter. 52.77% of the stock is owned by institutional investors.

argenx Price Performance

Shares of NASDAQ:ARGX opened at $514.77 on Friday. The firm has a 50 day simple moving average of $468.64 and a 200 day simple moving average of $412.09. The company has a market cap of $30.13 billion, a price-to-earnings ratio of -71.79 and a beta of 0.75. argenx SE has a one year low of $333.07 and a one year high of $550.76.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, July 27th. The company reported ($1.69) EPS for the quarter, meeting analysts’ consensus estimates of ($1.69). argenx had a negative return on equity of 27.99% and a negative net margin of 47.28%. The company had revenue of $281.16 million during the quarter, compared to analysts’ expectations of $258.32 million. During the same period in the prior year, the company earned ($3.81) EPS. As a group, analysts expect that argenx SE will post -5.33 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. UBS Group cut argenx from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $480.00 to $570.00 in a report on Monday, July 24th. Evercore ISI started coverage on shares of argenx in a research report on Monday, July 17th. They issued an “outperform” rating and a $436.00 target price for the company. Bank of America raised their price target on shares of argenx from $446.00 to $572.00 in a research report on Tuesday, July 18th. Jefferies Financial Group boosted their price objective on shares of argenx from $497.00 to $513.00 in a report on Monday, July 17th. Finally, Piper Sandler raised their target price on shares of argenx from $595.00 to $600.00 and gave the stock an “overweight” rating in a report on Thursday. One research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $522.73.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.